Jim Cramer: Viking Has 'Many Ships Coming In' (CORRECTED)
Portfolio Pulse from Avi Kapoor
Jim Cramer recommends buying Viking Therapeutics due to its strong prospects. JPMorgan has an Overweight rating on Viking with a price target of $80. Gentex is struggling due to its ties to the auto industry. Cadre Holdings reported strong earnings, while Celsius Holdings faces unspecified issues.
September 20, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Celsius Holdings faces unspecified issues, raising concerns about its current business situation.
Cramer's comment about unspecified issues with Celsius Holdings suggests potential problems, which could negatively impact investor sentiment and stock price.
CONFIDENCE 70
IMPORTANCE 65
RELEVANCE 60
NEGATIVE IMPACT
Gentex is facing challenges due to its close ties to the struggling auto industry, with no quick recovery expected.
Gentex's performance is closely tied to the auto industry, which is currently struggling. This suggests potential downside risk for the stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Cadre Holdings reported strong earnings, beating analyst expectations, indicating positive business performance.
Cadre's earnings beat suggests strong business performance, likely leading to positive investor sentiment and potential stock price increase.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 70
POSITIVE IMPACT
Jim Cramer recommends Viking Therapeutics, supported by JPMorgan's Overweight rating and $80 price target, indicating strong growth potential.
Cramer's positive recommendation and JPMorgan's Overweight rating with a significant price target suggest strong investor confidence and potential price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100